Dr. Fahrenholtz’s lab seeks to understand the genetic and molecular mechanisms that drive both difficult-to-treat cancers and cases of acquired resistance to therapy. Using this information, we are developing new ways to stratify patients and treat cancer using rational combinations of nanomedicine and conventional therapies. The Fahrenholtz lab is currently investigating several combination therapies that may improve patient outcomes while reducing both required dose and off-target effects.